
    
      This is an open-label study that will be conducted at a single site in China to characterize
      the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon
      alpha2a Fusion Protein in healthy subjects. Subjects will receive a single dose of
      Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein or active comparator
      Pegasys at Day 0. The total duration of study participation is up to 6 weeks for each
      subject. Subjects will complete a follow-up visit at Day 28 after the dosing.
    
  